logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals - Proactive One2One Investor Forum May 2019

Faron Pharmaceuticals Ltd’s (LON:FARN) chief executive Markku Jalkanen presents at the Proactive Investors One2One Investor Forum  in London May 2019.

For more information visit www.faron.com

Quick facts: Faron Pharmaceuticals Ltd

Price: 172.5 GBX

AIM:FARN
Market: AIM
Market Cap: £74.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

on 16/10/19

2 min read